

Pulocimab Biosimilar - Research Grade

Product Code: ICH5792

More Information

Species Reactivity: Human

Target: KDR α 1/2

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Pulocimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P35968

Shipping Conditions: Blue ice

background: KDR (VEGFR-2) is the dominant receptor mediating VEGF-driven angiogenesis. Modeled on pulocimab, this unconjugated, non-therapeutic human IgG1 kappa antibody is produced in CHO cells against human KDR. For research use only, it is formulated to low endotoxin for in vivo suitability and supplied in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It is well suited to receptor-blockade functional assays, angiogenesis studies, in vitro screening, and preclinical vascular and tumor models. Uniform quality across lots underpins confident comparisons in long-running projects.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE



Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks